<DOC>
	<DOCNO>NCT01362725</DOCNO>
	<brief_summary>The primary objective feasibility study determine safety spinal cord stimulation ( SCS ) therapy patient systolic heart failure gather observational information potential efficacy marker</brief_summary>
	<brief_title>Spinal Cord Stimulation For Heart Failure</brief_title>
	<detailed_description>Morbidity mortality heart failure patient remain relatively high , even recent advance therapy . Previous study show autonomic nervous system play important role pathophysiology heart failure ( HF ) sudden cardiac death . SCS neurostimulation therapy , involve stimulation select nerve fiber intend create end-organ response characterize change blood flow , decrease catecholamine reduction inflammation . These change occur due SCS show effective reducing symptom chronic angina pain secondary peripheral vascular disease situation characterize decreased blood flow inflammation . The SCS system consist implantable pulse generator ( IPG ) lead ( ) . Each lead electrodes distal end . Electrical impulse travel IPG lead electrode position select nerve fiber provide therapeutic stimulation . By virtue potential augmenting blood flow , decrease catecholamine reduce inflammation , SCS may benefit patient heart failure ( HF ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>Patients LVEF 20 % 35 % Patient NYHA Class III Ambulatory Class IV Patient SJM implantable cardioverter defibrillator ( ICD ) device SJM CRTD device implant &gt; 90 day receive stable medical therapy HF ( &gt; 90 day ) Baseline Patient LV end diastolic diameter 55mm 80mm Patient must able willing provide write informed consent participate study Patient must able willing comply require followup schedule Patient currently implant spinal cord stimulator previously implant spinal cord stimulator explanted Patient polyneuropathy Patient require shortwave diathermy , microwave diathermy therapeutic ultrasound diathermy Patient receive tissue / organ transplant ( expect tissue / organ transplant within next 180 day ) Patient persistent permanent Atrial Fibrillation ( AF ) Patient chronic refractory angina peripheral vascular pain Patient critical valvular heart disease require valve repair replacement Patient myocardial infarction ( MI ) cardiac revascularization procedure ( percutaneous coronary intervention coronary artery bypass graft ) &lt; 90 day Baseline expect next 180 day Patient IV inotropic therapy Patient active myocarditis early postpartum cardiomyopathy Patient take follow drug within 30 day enrollment : systemic corticosteroid , cytostatic immunosuppressive drug therapy ( cyclophosphamide , methotrexate , cyclosporine , azathioprine , etc . ) , DNA deplete cytotoxic drug Patient pregnant , childbearing potential use adequate contraceptive method , nurse Patient bleeding tendency ( International Normalized Ratio , INR &gt; 1.2 platelet count &lt; 100 x109 per liter ) Patient local infection ICD implant location systemic infection Patient renal insufficiency ( creatinine &gt; 3.0 mg/dl ) Patient participate another clinical study Patient le 18 year old Patient 's life 's expectancy le 1 year assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>spinal cord stimulation</keyword>
	<keyword>systolic heart failure</keyword>
</DOC>